Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275295 | 0.88 | ALDH1A1 (0.47) | ALDH1A1MAPTTDP1KDM4ENPC1 | |
| SCHEMBL14533084 | 0.87 | ALDH1A1 (0.38) | ALDH1A1MAPTTDP1KDM4ENPC1 | |
| SCHEMBL2772250 | 0.85 | MAPT (0.47) | ALDH1A1MAPTTDP1KDM4ENPC1 | |
| SCHEMBL2214991 | 0.85 | ALDH1A1 (0.59) | ALDH1A1MAPTTDP1KDM4ENPC1 | |
| SCHEMBL2933245 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MAPTTDP1KDM4EL3MBTL1 | |
| SCHEMBL31126043 | 0.84 | ALDH1A1 (0.54) | ALDH1A1MAPTTDP1KDM4EL3MBTL1 | |
| SCHEMBL13675024 | 0.80 | NR4A1 (0.53) | ALDH1A1MAPTKDM4ERAB9AL3MBTL1 | |
| SCHEMBL8229668 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTTDP1KDM4ENPC1 | |
| SCHEMBL4860242 | 0.78 | PARP1 (0.56) | ALDH1A1TDP1KDM4ERAB9AHPGD | |
| SCHEMBL19050286 | 0.76 | HSP90AA1 (0.40) | ALDH1A1MAPTTDP1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111779-A1 | METHODS OF MANUFACTURE OF DIANHYDRIDES | CHAULAGAIN MANI RAJ (US) | 2023-04-13 | — | — | US | disclosed |
| EP-4143157-A1 | METHODS OF MANUFACTURE OF DIANHYDRIDES | Chaulagain, Mani (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021252169-A1 | METHODS OF MANUFACTURE OF DIANHYDRIDES | CHAULAGAIN MANI (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-3955256-A | Process for the production of a carbon tape | CELANESE CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885MAPT 3874/4885TDP1 2092/4885 |
| US-20230111779-A1 | METHODS OF MANUFACTURE OF DIANHYDRIDES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NISCH, HDHD5 | ALDH1A1 2807/4885MAPT 693/4885TDP1 3005/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ALDH1A1 1061/4885MAPT 1964/4885TDP1 2274/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ALDH1A1 1061/4885MAPT 1964/4885TDP1 2274/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | ALDH1A1 2244/4885MAPT 3874/4885TDP1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.